Navigation Links
Replidyne Announces 2007 Fourth Quarter and Full Year Results
Date:2/26/2008

er full year contingent supply agreement costs related to the faropenem program and $1.5 million of product acquisition cost in 2006 to complete the purchase of tRNA synthetase technology from GlaxoSmithKline which includes Replidyne's C. difficile program and REP8839.

Sales, general and administrative expenses for the fourth quarter of 2007 were $3.2 million compared to $3.5 million in the fourth quarter of 2006 reflecting lower marketing study expenses in the 2007 quarter. Included in the 2007 quarter result was $0.6 million related to the organizational restructuring implemented on December 10, 2007. Full year 2007 selling, general and administrative expenses were $13 million compared to $12.2 million in 2006 reflecting increased full year compensation costs, restructuring expense, and increased professional fees related to public company compliance.

Investment income for the fourth quarter of 2007 was $1.2 million compared to $1.7 million for the fourth quarter of 2006, primarily reflecting lower cash balances available for investment in the 2007 period. Full year 2007 investment income was $5.5 million compared to $6.0 million 2006.

As reported in its 2006 results, through July 3, 2006 Replidyne recorded dividends due to preferred shareholders of $5.4 million. All outstanding preferred stock and accumulated dividends were converted into common stock upon closing of the initial public offering on July 3, 2006 and no preferred stock or accrued dividends were outstanding after that date.

Conference Call Information

Replidyne will host a conference call and webcast today, February 26, 2008, at 4:45 P.M. EST to discuss 2007 fourth quarter and full year financial results and update the Company's expectations. Callers may participate in the conference call by dialing 866-510-0707 (domestic) or 617-597-5376 (international), and providing the passcode 33794809. To access the live webcast, log on to the Company's website at

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Whitehouse Laboratories has formally announced ... Testing and Package Test Capacity. Responding to growing demands ... dramatic increase in environmental chamber storage space that will ... aging samples to be securely held on site at ... expenditure has already taken place with the recent completion ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear (GIS) ... & Secondary), and End-User (Transmission & Distribution, Manufacturing ... - Trends and Forecasts to 2019”, defines and ... of the market size. , Browse more than ... through 146 Pages and in-depth TOC on “Gas ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Oct. 10 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) ... a placement to Australian, U.S., Asian and European ... balance,sheet as Pharmaxis continues with a series of ... of its manufacturing operation in,Sydney. Pharmaxis will ...
... October 10 The National,Institutes of Allergy and ... with Bavarian Nordic to include the initiation of,a ... investigational,smallpox vaccine, in persons diagnosed with atopic dermatitis. ... 2010 and has a value of,US$15 million, with ...
... OPK ),today announced that it has acquired exclusive ... compound with potential utility,in the treatment of dry eye. ... can disrupt the lives,of those afflicted. It can cause ... Sam Reich, Executive Vice President,of Ophthalmologics at OPKO. "There ...
Cached Biology Technology:Pharmaxis Announces Placement of $50 Million and Share Purchase Plan 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 3OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye 2OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye 3
(Date:10/30/2014)... 30 October 2014 Biological membranes are mainly composed ... adsorption of solution ions onto lipid membranes helps ... new study provides a quantitative description of the ... Joanna Kotyńska and Zbigniew Figaszewski from the University ... study describing these findings, just published in ...
(Date:10/29/2014)... OR) New research presented at the Society ... Houston, TX showed for the first time that ... women using a readily available nutritional supplement, AHCC. ... Dr. Judith A. Smith, Pharm.D., associate professor in ... at The University of Texas Health Science Center ...
(Date:10/29/2014)... the safety of nanoparticles is all the rage. Thousands ... examining the question of whether titanium dioxide nanoparticles from ... the body, whether carbon nanotubes from electronic products are ... be or whether nanoparticles in food can get into ... interest is great, research funds are flowing – and ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... Scientists and engineers must join together in a major new ... crisis in providing Earth,s people with clean water that looms ... comment article in the current edition of Chemical & ... Society (ACS), the world,s largest scientific society. Bassam Z. ...
... of potential environmental and human health effects from disposal ... led scientists to recommend stronger government policies to encourage ... That,s the conclusion of a new paper in the ... Oladele A. Ogunseitan and colleagues point out that Li-ion ...
... life scientists provide important new details on how climate change ... 21 in the Journal of Animal Ecology . This ... informing policymakers of how species are likely to be impacted ... recognition among biologists that climate change is affecting how species ...
Cached Biology News:UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... BioNumerics is the universal bioinformatics software that ... data. The unique modular design of BioNumerics ... virtually any type of data employed for ... microarrays, DNA fingerprints, 2-D protein gels, HPLC, ...
... early 80s Biosearch Technologies has been ... tools to accelerate the discovery and ... need dual-labeled FRET probes and primers ... for microarray applications, Biosearch can meet ...
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
Biology Products: